CVL-354
| Clinical data | |
|---|---|
| Routes of administration | Oral administration |
| Drug class | Opioid antagonist; κ-Opioid receptor antagonist |
CVL-354 is an opioid antagonist which is under development for the treatment of major depressive disorder and substance-related disorders.[1][2]
It acts as a selective antagonist of the κ-opioid receptor.[1][2] The drug is also more weakly an antagonist of the μ-opioid receptor, with about 31-fold lower affinity and 27-fold lower inhibitory potency at the μ-opioid receptor relative to the κ-opioid receptor.[2] CVL-354 is taken by mouth.[1] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] As of September 2022, CVL-354 is in phase 1 clinical trials for major depressive disorder and is in the preclincal stage of development for substance-related disorders.[1]
See also
References
- 1 2 3 4 5 "CVL 354 – Cerevel therapeutics". Adis Insight. Springer Nature Switzerland AG.
- 1 2 3 "ACNP 61st Annual Meeting: Poster Abstracts P271-P540". Neuropsychopharmacology. 47 (Suppl 1): 220–370. December 2022. doi:10.1038/s41386-022-01485-0. eISSN 1740-634X. PMC 9714399. PMID 36456694.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.